vTv Therapeutics Inc.
vTv Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 31, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
vTv Therapeutics Inc. generates cash from operations, so a burn-based runway figure does not apply.
Across 12 concluded trials, 67% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 31, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2027 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Trial Milestone | Phase 3 |
| June 15, 2027 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems | Trial Milestone | Phase 2 |
Track VTVT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open VTVT in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.